Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2020 / N 4

Терапия единым ингалятором – современный подход к лечению бронхиальной астмы
А.В. Емельянов, Е.В. Лешенкова, Г.Р. Сергеева

References

1. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. Respiratory Medicine 2017 Sep;5(9):691-706.
2. Global Initiative for Asthma. Global strategy for asthma management and prevention (GINA). Updated 2021. Available from: https://ginasthma.org/gina-reports/ Accessed 2021 May 24.
3. Ministry of Healthcare of the Russian Federation. Bronchial asthma. Federal clinical guidelines. ICD 10: J.45, J.46. Year of approval: 2019. Moscow, 2019. 97 p. Available from: https://spulmo.ru/upload/kr_bronhastma_2019.pdf Accessed 2021 May 24 (In Russian).
4. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Primary Care Respiratory Medicine 2014 Jun;24(1):14009.
5. Arkhipov VV, Grigoryeva EV, Gavrishina EV. Control of bronchial asthma in Russia: results of NIKA multicenter observational study. Pulmonologiya 2011;6:87-93 (In Russian).
6. Yemelyanov AV, Goryachkina LA, Astafyeva NG, Fassakhov RS, Chernyak BA, Abelevich MM, Ignatova GL, Kudelya LM, Zhestkov AV, Leshchenko IV, Sobko EA, Alekseyenko VA, Burlachuk VT, Lobanov KI, Frolova SA, Galimova ES, Hassanova RB, Koroleva MG; Group of Investigators for ERAS program, Russia. Allergic rhinitis and asthma in real clinical practice: Russian multicenter clinical study. Russian Journal of Allergy 2012;9(1):29-36 (In Russian).
7. Howell G. Nonadherence to medical therapy in asthma: risk factors, barriers, and strategies for improving. The Journal of Asthma 2008 Nov;45(9):723-9.
8. Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitude and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulmonary Medicine 2006 Jun;6:13.
9. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New development. American Journal of Respiratory and Critical Care Medicine 1998 Mar;157(3 Pt 2):S1-53.
10. Global Initiative for Asthma. Global strategy for asthma management and prevention. Revised 2006. Chuchalin AG, editor. Moscow: Atmosphere; 2007. 104 p. (In Russian).
11. Gibson PJ, Saltos N, Fakes K. Acute anti-inflammatory effect of inhaled budesonide in asthma: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine 2001 Jan;163(1):32-6.
12. Kippelen P, Larsson J, Anderson SD, Brannan JD, Delin I, Dahlen B, Dahlen SV. Acute effects of beclomethasone on hyperpnea-induced bronchoconstriction. Medicine & Science in Sports & Exercise 2010 Feb;42(2):273-80.
13. Erin EM, Zachrasiewicz AS, Nicholson GC, Tan AJ, Higgins LA, Williams TJ, Murdoch RD, Durham SR, Barnes PJ, Hansel TT. Topical corticosteroid inhibits interleukin-4, -5 and -13 in nasal secretions following allergen challenge. Clinical & Experimental Allergy 2005;35(12):1608-14.
14. Barnes PJ. Scientific rationale for using a single inhaler for asthma control. The European Respiratory Journal 2007 Mar;29(3):587-95.
15. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. The European Respiratory Journal 1997;10(11):2484-9.
16. Anderson GP, Lindén A, Rabe KF. Why are long-acting beta-adrenoceptor agonists long-acting? The European Respiratory Journal 1994 Mar;7(3):569-78.
17. Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effect of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax 2000 Aug;55(8):650-6.
18. Rosenborg J, Bengtsson T, Larsson P, Blomgren A, Persson G, Lötvall J. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics. European Journal of Clinical Pharmacology 2000 Aug;56(5):363-70.
19. Ferrari M, Balestreri F, Baratieri S, Biasin C, Oldani V, Cascio VL. Evidence of the rapid protective effect of formoterol dry-powder inhalation against exercise-induced bronchospasm in athletes with asthma. Respiration 2000;67(5):510-3.
20. Ståhl E, Postma DS, Svensson K, Tattersfield AE, Eivindson A, Schreurs A, Löfdahl CG. Formoterol used as needed improves health-related quality of life in asthmatic patients uncontrolled with inhaled corticosteroids. Respiratory Medicine 2003 Sep;97(9):1061-6.
21. Tatersfield AE, Löfdahl CG, Postma DS, Eivindson A, Schreurs AG, Rasidakis A, Ekström T. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomized trial. The Lancet 2001;357(9252):257-61.
22. Tatersfield AE, Postma DS, Barnes P, Svensson K, Bauer CA, O’Byrne PM, Löfdahl CG, Pauwels RA, Ullman A. Exacerbations of asthma; a descriptive study of 425 severe exacerbations. The FACET International Study Group. American Journal of Respiratory and Critical Care Medicine 1999 Aug;160(2):594-9.
23. Adcock I, Maneechotesuwan K, Usmani O. Molecular interaction between glucocorticoids and long-acting beta2-agonists. The Journal of Allergy and Clinical Immunology 2002 Dec;110(6 Suppl):S261-8.
24. Ministry of Healthcare of the Russian Federation. Instructions for medical use of the Foster drug. Available from: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=67aaff0a-a580-4295-93e0-40badf2084f3&t= Accessed 2021 May 24. (In Russian).
25. Sobieraj DM, Weeda ER, Nguyen E, Coleman GI, White CM, Lazarus SC, Blake KV, Lang JE, Baker WL. Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. JAMA 2018 Apr;319(14):1485-96.
26. Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergiejko Z, Petruzzelli S, Fabbri LM, Rabe KF. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. The Lancet. Respiratory Medicine 2013 Mar;1(1):23-31.
27. Barnes PJ, Nicolini G, Bizzi A, Spinola M, Singh D. Do inhaled corticosteroid/long-acting beta-2-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal. Allergy and Asthma Proceedings 2012 Mar-Apr;33(2):140-4.
28. Avdeyev SN, Aysanov ZR, Arkhipov VV, Belevskiy AS, Gheppe NA, Ilkovich MM, Knyazheskaya NP, Nenasheva NM, Ovcharenko SI, Stepanyan IE, Fassakhov RS, Shmelev EI. Therapy recommendations for bronchial asthma and chronic obstructive pulmonary disease according disease phenotype and small respiratory tract role. Atmosphere. Pulmonology and Allergology 2013;2:15-26 (In Russian).
29. Postma DS, Brightling C, Baldi S, Van den Berge M, Fabbri LM, Gagnatelli A, Papi A, Van der Molen T, Rabe KF, Siddiqui S, Singh D, Nicolini G, Kraft M; ATLANTIS study group. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. The Lancet. Respiratory Medicine 2019 May;7(5):402-16.
30. O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Ivanov S, Reddel HK. Inhaled combined budesonide-formoterol as needed in mild asthma. The New England Journal of Medicine 2018 May;378(20):1865-76.
31. Bateman ED, Reddel HK, O’Byrne PM, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Siwek-Posluszna A, FitzGerald JM. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. The New England Journal of Medicine 2018 May;378(20):1877-87.
32. Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, Harrison T, Houghton C, Oldfield K, Papi A, Pavord ID, Williams M, Weatherall M; Novel START Study Team. Controlled trial of budesonide-formoterol as needed for mild asthma. The New England Journal of Medicine 2019 May;380(21):2020-30.
33. Cruz A, Barile S, Nudo E, Brogelli L, Guller P, Papi A. ICS/formoterol in the management of asthma in the clinical practice of pulmonologists: an international survey on GINA strategy. Asthma Research and Practice 2021 Jan;7(1):1.
  

[ Содержание выпуска N 4 | Выпуски журнала | Список журналов ]